Inicio › Leucemia mielógena aguda › Míchigan › Detroit
Ensayos clínicos de Leucemia mielógena aguda en Detroit, MI
14 estudios para Leucemia mielógena aguda buscan participantes en centros de Detroit y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutandoFase 3
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
ReclutandoFase 3
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutandoFase 2
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutandoFase 1
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
ReclutandoEstudio observacional
- Henry Ford Health, Detroit
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
Otros estudios en Detroit
- Cáncer de pulmón de células no pequeñas44 estudios
- Cáncer de seno33 estudios
- Cáncer (todos los tipos)29 estudios
- Cáncer del colon y del recto26 estudios
- Cáncer de ovario26 estudios
- Cáncer metastásico24 estudios
- Cáncer de próstata22 estudios
- Cáncer de endometrio21 estudios
- Cáncer de pulmón20 estudios
- Mieloma múltiple19 estudios
- Cáncer de estómago16 estudios
- Carcinoma de células escamosas de cabeza y cuello15 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.